Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia
Gender differences in tumor size are supposed to exist in hyperprolactinemia since microadenomas are more commonly found in women and macroadenomas in men. Whether this reflects only a delay in diagnosis in men or a true gender difference in tumor pathogenesis is still unclear. To prospectively anal...
Gespeichert in:
| Veröffentlicht in: | European journal of endocrinology 2003-03, Vol.148 (3), p.325-331 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 331 |
|---|---|
| container_issue | 3 |
| container_start_page | 325 |
| container_title | European journal of endocrinology |
| container_volume | 148 |
| creator | COLAO, Annamaria DI SARNO, Antonella CAPPABIANCA, Paolo BRIGANTI, Francesco PIVONELLO, Rosario DI SOMMA, Carolina FAGGIANO, Antongiulio BIONDI, Bernadette LOMBARDI, Gaetano |
| description | Gender differences in tumor size are supposed to exist in hyperprolactinemia since microadenomas are more commonly found in women and macroadenomas in men. Whether this reflects only a delay in diagnosis in men or a true gender difference in tumor pathogenesis is still unclear.
To prospectively analyze gender differences in the presentation and response to cabergoline treatment in 219 consecutive newly diagnosed patients with hyperprolactinemia.
An open prospective design.
Of the 219 patients of which 145 were women; 107 patients had macroprolactinoma, 97 had microprolactinoma, and 15 had non-tumoral hyperprolactinemia.
Presenting clinical symptoms, prolactin levels and tumor size at magnetic resonance imaging were measured before and 3-6 Months after cabergoline therapy.
Prevalence of microprolactinomas (56% vs 22%, P= |
| doi_str_mv | 10.1530/eje.0.1480325 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73071702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73071702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-12188802d51ca35c15d7798a0df562252528f88a6ed515b10306c0688d2f94cd3</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhoMotlaPXiUXPbk1H5tsepSiVSh4UfC2pMnEpuyXya7Qf29KF8oc5mV4eAcehG4pmVPByRPsYJ5irghn4gxNaV4sMqn49zmaEkXyLJc5n6CrGHeE0JTJJZpQJimVlE-RX0FjIWDrnYMAjYGIfYP7LeAuwJ-uDqdHbCrfeKMr7ED3Q0iQbixOu2ubCLhvsdEbCD9t4uBQsN13ELrQVtr06VR7fY0unK4i3Ix7hr5eXz6Xb9n6Y_W-fF5nhivRZ5RRpRRhVlCjuTBU2KJYKE2sE5IxkUY5pbSERIgNJZxIQ6RSlrlFbiyfoYdjb_r-O0Dsy9pHA1WlG2iHWBacFLQgLIHZETShjTGAK7vgax32JSXlwW2Z3JYpHt0m_m4sHjY12BM9ykzA_QjomFy5oBvj44nLJaecFfwfTQ6CLA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73071702</pqid></control><display><type>article</type><title>Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>COLAO, Annamaria ; DI SARNO, Antonella ; CAPPABIANCA, Paolo ; BRIGANTI, Francesco ; PIVONELLO, Rosario ; DI SOMMA, Carolina ; FAGGIANO, Antongiulio ; BIONDI, Bernadette ; LOMBARDI, Gaetano</creator><creatorcontrib>COLAO, Annamaria ; DI SARNO, Antonella ; CAPPABIANCA, Paolo ; BRIGANTI, Francesco ; PIVONELLO, Rosario ; DI SOMMA, Carolina ; FAGGIANO, Antongiulio ; BIONDI, Bernadette ; LOMBARDI, Gaetano</creatorcontrib><description><![CDATA[Gender differences in tumor size are supposed to exist in hyperprolactinemia since microadenomas are more commonly found in women and macroadenomas in men. Whether this reflects only a delay in diagnosis in men or a true gender difference in tumor pathogenesis is still unclear.
To prospectively analyze gender differences in the presentation and response to cabergoline treatment in 219 consecutive newly diagnosed patients with hyperprolactinemia.
An open prospective design.
Of the 219 patients of which 145 were women; 107 patients had macroprolactinoma, 97 had microprolactinoma, and 15 had non-tumoral hyperprolactinemia.
Presenting clinical symptoms, prolactin levels and tumor size at magnetic resonance imaging were measured before and 3-6 Months after cabergoline therapy.
Prevalence of microprolactinomas (56% vs 22%, P=<0.0001) and non-tumoral hyperprolactinemia (10% vs 0%, P=0.01) was higher in women than in men. Men and women were of similar age (median 32 vs 29 Years; P=0.2) and a similar number had gonadal/sexual dysfunction (85 vs 83%, P=0.6); weight gain (70 vs 46%; P=<0.0001) and galactorrhea (52 vs 19%; P=<0.0001) were more common in women. Prolactin levels were higher in men than in women, whether exhibiting macro- (2848+/-2954 vs 1132+/-2351 microg/l, P=<0.0001) or microadenomas (187.8+/-51.8 vs 135.4+/-60.5 microg/l, P=0.009) and the size of the adenoma was larger in men than in women irrespective of macro- (25.8+/-12.4 vs 17.2+/-7.2 mm, P=<0.0001) or microadenoma diagnosis (8.0+/-1.4 vs 7.1+/-1.6 mm, P=0.04). After treatment, prolactin levels decreased by 89.2-96.4% in all groups, and normalized more frequently in micro- than in macroadenoma patients (86 vs 64%, P<0.0001), regardless of gender (70% vs 69%, P=0.9). Menses resumed in 82% of women, libido disturbances improved in 57% of men. Tumor size was reduced by 45+/-25% and 52+/-24% in macroprolactinoma patients and by 44+/-31 and 38+/-29% in microprolactinoma patients in women and men respectively. Visual field defects disappeared in 61% of women and in 71% of men (P=0.6).
Prevalence of macroprolactinomas was similar in men and women; microprolactinomas and non-tumoral hyperprolactinemia were more frequent in women. Clinical symptoms at presentation differed according to gender, with galactorrhea and weight gain more frequent in women. The successful response to cabergoline treatment for 6 Months was higher in micro- than in macroprolactinoma patients and was similar in women and men.]]></description><identifier>ISSN: 0804-4643</identifier><identifier>EISSN: 1479-683X</identifier><identifier>DOI: 10.1530/eje.0.1480325</identifier><identifier>PMID: 12611613</identifier><language>eng</language><publisher>Colchester: Portland Press</publisher><subject>Adolescent ; Adult ; Aged ; Analysis. Health state ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Cabergoline ; Endocrinopathies ; Epidemiology ; Ergolines - therapeutic use ; Female ; Follow-Up Studies ; Galactose - blood ; General aspects ; Humans ; Hyperprolactinemia - drug therapy ; Hyperprolactinemia - epidemiology ; Hyperprolactinemia - physiopathology ; Hypothalamus. Hypophysis. Epiphysis (diseases) ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Pituitary Neoplasms - drug therapy ; Pituitary Neoplasms - pathology ; Pituitary Neoplasms - physiopathology ; Prolactin - blood ; Prolactinoma - drug therapy ; Prolactinoma - pathology ; Prolactinoma - physiopathology ; Prospective Studies ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Sex Characteristics ; Sexual Dysfunction, Physiological - etiology ; Treatment Outcome ; Visual Fields - physiology ; Weight Gain</subject><ispartof>European journal of endocrinology, 2003-03, Vol.148 (3), p.325-331</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-12188802d51ca35c15d7798a0df562252528f88a6ed515b10306c0688d2f94cd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14631327$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12611613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>COLAO, Annamaria</creatorcontrib><creatorcontrib>DI SARNO, Antonella</creatorcontrib><creatorcontrib>CAPPABIANCA, Paolo</creatorcontrib><creatorcontrib>BRIGANTI, Francesco</creatorcontrib><creatorcontrib>PIVONELLO, Rosario</creatorcontrib><creatorcontrib>DI SOMMA, Carolina</creatorcontrib><creatorcontrib>FAGGIANO, Antongiulio</creatorcontrib><creatorcontrib>BIONDI, Bernadette</creatorcontrib><creatorcontrib>LOMBARDI, Gaetano</creatorcontrib><title>Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia</title><title>European journal of endocrinology</title><addtitle>Eur J Endocrinol</addtitle><description><![CDATA[Gender differences in tumor size are supposed to exist in hyperprolactinemia since microadenomas are more commonly found in women and macroadenomas in men. Whether this reflects only a delay in diagnosis in men or a true gender difference in tumor pathogenesis is still unclear.
To prospectively analyze gender differences in the presentation and response to cabergoline treatment in 219 consecutive newly diagnosed patients with hyperprolactinemia.
An open prospective design.
Of the 219 patients of which 145 were women; 107 patients had macroprolactinoma, 97 had microprolactinoma, and 15 had non-tumoral hyperprolactinemia.
Presenting clinical symptoms, prolactin levels and tumor size at magnetic resonance imaging were measured before and 3-6 Months after cabergoline therapy.
Prevalence of microprolactinomas (56% vs 22%, P=<0.0001) and non-tumoral hyperprolactinemia (10% vs 0%, P=0.01) was higher in women than in men. Men and women were of similar age (median 32 vs 29 Years; P=0.2) and a similar number had gonadal/sexual dysfunction (85 vs 83%, P=0.6); weight gain (70 vs 46%; P=<0.0001) and galactorrhea (52 vs 19%; P=<0.0001) were more common in women. Prolactin levels were higher in men than in women, whether exhibiting macro- (2848+/-2954 vs 1132+/-2351 microg/l, P=<0.0001) or microadenomas (187.8+/-51.8 vs 135.4+/-60.5 microg/l, P=0.009) and the size of the adenoma was larger in men than in women irrespective of macro- (25.8+/-12.4 vs 17.2+/-7.2 mm, P=<0.0001) or microadenoma diagnosis (8.0+/-1.4 vs 7.1+/-1.6 mm, P=0.04). After treatment, prolactin levels decreased by 89.2-96.4% in all groups, and normalized more frequently in micro- than in macroadenoma patients (86 vs 64%, P<0.0001), regardless of gender (70% vs 69%, P=0.9). Menses resumed in 82% of women, libido disturbances improved in 57% of men. Tumor size was reduced by 45+/-25% and 52+/-24% in macroprolactinoma patients and by 44+/-31 and 38+/-29% in microprolactinoma patients in women and men respectively. Visual field defects disappeared in 61% of women and in 71% of men (P=0.6).
Prevalence of macroprolactinomas was similar in men and women; microprolactinomas and non-tumoral hyperprolactinemia were more frequent in women. Clinical symptoms at presentation differed according to gender, with galactorrhea and weight gain more frequent in women. The successful response to cabergoline treatment for 6 Months was higher in micro- than in macroprolactinoma patients and was similar in women and men.]]></description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Analysis. Health state</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cabergoline</subject><subject>Endocrinopathies</subject><subject>Epidemiology</subject><subject>Ergolines - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Galactose - blood</subject><subject>General aspects</subject><subject>Humans</subject><subject>Hyperprolactinemia - drug therapy</subject><subject>Hyperprolactinemia - epidemiology</subject><subject>Hyperprolactinemia - physiopathology</subject><subject>Hypothalamus. Hypophysis. Epiphysis (diseases)</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Pituitary Neoplasms - drug therapy</subject><subject>Pituitary Neoplasms - pathology</subject><subject>Pituitary Neoplasms - physiopathology</subject><subject>Prolactin - blood</subject><subject>Prolactinoma - drug therapy</subject><subject>Prolactinoma - pathology</subject><subject>Prolactinoma - physiopathology</subject><subject>Prospective Studies</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Sex Characteristics</subject><subject>Sexual Dysfunction, Physiological - etiology</subject><subject>Treatment Outcome</subject><subject>Visual Fields - physiology</subject><subject>Weight Gain</subject><issn>0804-4643</issn><issn>1479-683X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQhoMotlaPXiUXPbk1H5tsepSiVSh4UfC2pMnEpuyXya7Qf29KF8oc5mV4eAcehG4pmVPByRPsYJ5irghn4gxNaV4sMqn49zmaEkXyLJc5n6CrGHeE0JTJJZpQJimVlE-RX0FjIWDrnYMAjYGIfYP7LeAuwJ-uDqdHbCrfeKMr7ED3Q0iQbixOu2ubCLhvsdEbCD9t4uBQsN13ELrQVtr06VR7fY0unK4i3Ix7hr5eXz6Xb9n6Y_W-fF5nhivRZ5RRpRRhVlCjuTBU2KJYKE2sE5IxkUY5pbSERIgNJZxIQ6RSlrlFbiyfoYdjb_r-O0Dsy9pHA1WlG2iHWBacFLQgLIHZETShjTGAK7vgax32JSXlwW2Z3JYpHt0m_m4sHjY12BM9ykzA_QjomFy5oBvj44nLJaecFfwfTQ6CLA</recordid><startdate>20030301</startdate><enddate>20030301</enddate><creator>COLAO, Annamaria</creator><creator>DI SARNO, Antonella</creator><creator>CAPPABIANCA, Paolo</creator><creator>BRIGANTI, Francesco</creator><creator>PIVONELLO, Rosario</creator><creator>DI SOMMA, Carolina</creator><creator>FAGGIANO, Antongiulio</creator><creator>BIONDI, Bernadette</creator><creator>LOMBARDI, Gaetano</creator><general>Portland Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030301</creationdate><title>Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia</title><author>COLAO, Annamaria ; DI SARNO, Antonella ; CAPPABIANCA, Paolo ; BRIGANTI, Francesco ; PIVONELLO, Rosario ; DI SOMMA, Carolina ; FAGGIANO, Antongiulio ; BIONDI, Bernadette ; LOMBARDI, Gaetano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-12188802d51ca35c15d7798a0df562252528f88a6ed515b10306c0688d2f94cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Analysis. Health state</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cabergoline</topic><topic>Endocrinopathies</topic><topic>Epidemiology</topic><topic>Ergolines - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Galactose - blood</topic><topic>General aspects</topic><topic>Humans</topic><topic>Hyperprolactinemia - drug therapy</topic><topic>Hyperprolactinemia - epidemiology</topic><topic>Hyperprolactinemia - physiopathology</topic><topic>Hypothalamus. Hypophysis. Epiphysis (diseases)</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Pituitary Neoplasms - drug therapy</topic><topic>Pituitary Neoplasms - pathology</topic><topic>Pituitary Neoplasms - physiopathology</topic><topic>Prolactin - blood</topic><topic>Prolactinoma - drug therapy</topic><topic>Prolactinoma - pathology</topic><topic>Prolactinoma - physiopathology</topic><topic>Prospective Studies</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Sex Characteristics</topic><topic>Sexual Dysfunction, Physiological - etiology</topic><topic>Treatment Outcome</topic><topic>Visual Fields - physiology</topic><topic>Weight Gain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>COLAO, Annamaria</creatorcontrib><creatorcontrib>DI SARNO, Antonella</creatorcontrib><creatorcontrib>CAPPABIANCA, Paolo</creatorcontrib><creatorcontrib>BRIGANTI, Francesco</creatorcontrib><creatorcontrib>PIVONELLO, Rosario</creatorcontrib><creatorcontrib>DI SOMMA, Carolina</creatorcontrib><creatorcontrib>FAGGIANO, Antongiulio</creatorcontrib><creatorcontrib>BIONDI, Bernadette</creatorcontrib><creatorcontrib>LOMBARDI, Gaetano</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>COLAO, Annamaria</au><au>DI SARNO, Antonella</au><au>CAPPABIANCA, Paolo</au><au>BRIGANTI, Francesco</au><au>PIVONELLO, Rosario</au><au>DI SOMMA, Carolina</au><au>FAGGIANO, Antongiulio</au><au>BIONDI, Bernadette</au><au>LOMBARDI, Gaetano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia</atitle><jtitle>European journal of endocrinology</jtitle><addtitle>Eur J Endocrinol</addtitle><date>2003-03-01</date><risdate>2003</risdate><volume>148</volume><issue>3</issue><spage>325</spage><epage>331</epage><pages>325-331</pages><issn>0804-4643</issn><eissn>1479-683X</eissn><abstract><![CDATA[Gender differences in tumor size are supposed to exist in hyperprolactinemia since microadenomas are more commonly found in women and macroadenomas in men. Whether this reflects only a delay in diagnosis in men or a true gender difference in tumor pathogenesis is still unclear.
To prospectively analyze gender differences in the presentation and response to cabergoline treatment in 219 consecutive newly diagnosed patients with hyperprolactinemia.
An open prospective design.
Of the 219 patients of which 145 were women; 107 patients had macroprolactinoma, 97 had microprolactinoma, and 15 had non-tumoral hyperprolactinemia.
Presenting clinical symptoms, prolactin levels and tumor size at magnetic resonance imaging were measured before and 3-6 Months after cabergoline therapy.
Prevalence of microprolactinomas (56% vs 22%, P=<0.0001) and non-tumoral hyperprolactinemia (10% vs 0%, P=0.01) was higher in women than in men. Men and women were of similar age (median 32 vs 29 Years; P=0.2) and a similar number had gonadal/sexual dysfunction (85 vs 83%, P=0.6); weight gain (70 vs 46%; P=<0.0001) and galactorrhea (52 vs 19%; P=<0.0001) were more common in women. Prolactin levels were higher in men than in women, whether exhibiting macro- (2848+/-2954 vs 1132+/-2351 microg/l, P=<0.0001) or microadenomas (187.8+/-51.8 vs 135.4+/-60.5 microg/l, P=0.009) and the size of the adenoma was larger in men than in women irrespective of macro- (25.8+/-12.4 vs 17.2+/-7.2 mm, P=<0.0001) or microadenoma diagnosis (8.0+/-1.4 vs 7.1+/-1.6 mm, P=0.04). After treatment, prolactin levels decreased by 89.2-96.4% in all groups, and normalized more frequently in micro- than in macroadenoma patients (86 vs 64%, P<0.0001), regardless of gender (70% vs 69%, P=0.9). Menses resumed in 82% of women, libido disturbances improved in 57% of men. Tumor size was reduced by 45+/-25% and 52+/-24% in macroprolactinoma patients and by 44+/-31 and 38+/-29% in microprolactinoma patients in women and men respectively. Visual field defects disappeared in 61% of women and in 71% of men (P=0.6).
Prevalence of macroprolactinomas was similar in men and women; microprolactinomas and non-tumoral hyperprolactinemia were more frequent in women. Clinical symptoms at presentation differed according to gender, with galactorrhea and weight gain more frequent in women. The successful response to cabergoline treatment for 6 Months was higher in micro- than in macroprolactinoma patients and was similar in women and men.]]></abstract><cop>Colchester</cop><pub>Portland Press</pub><pmid>12611613</pmid><doi>10.1530/eje.0.1480325</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0804-4643 |
| ispartof | European journal of endocrinology, 2003-03, Vol.148 (3), p.325-331 |
| issn | 0804-4643 1479-683X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73071702 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Adolescent Adult Aged Analysis. Health state Antineoplastic Agents - therapeutic use Biological and medical sciences Cabergoline Endocrinopathies Epidemiology Ergolines - therapeutic use Female Follow-Up Studies Galactose - blood General aspects Humans Hyperprolactinemia - drug therapy Hyperprolactinemia - epidemiology Hyperprolactinemia - physiopathology Hypothalamus. Hypophysis. Epiphysis (diseases) Magnetic Resonance Imaging Male Medical sciences Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms Pituitary Neoplasms - drug therapy Pituitary Neoplasms - pathology Pituitary Neoplasms - physiopathology Prolactin - blood Prolactinoma - drug therapy Prolactinoma - pathology Prolactinoma - physiopathology Prospective Studies Public health. Hygiene Public health. Hygiene-occupational medicine Sex Characteristics Sexual Dysfunction, Physiological - etiology Treatment Outcome Visual Fields - physiology Weight Gain |
| title | Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T23%3A09%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gender%20differences%20in%20the%20prevalence,%20clinical%20features%20and%20response%20to%20cabergoline%20in%20hyperprolactinemia&rft.jtitle=European%20journal%20of%20endocrinology&rft.au=COLAO,%20Annamaria&rft.date=2003-03-01&rft.volume=148&rft.issue=3&rft.spage=325&rft.epage=331&rft.pages=325-331&rft.issn=0804-4643&rft.eissn=1479-683X&rft_id=info:doi/10.1530/eje.0.1480325&rft_dat=%3Cproquest_cross%3E73071702%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73071702&rft_id=info:pmid/12611613&rfr_iscdi=true |